Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYRRHINIL-INTEST versus placebo in IBS-D and IBS-M
2019-000245-12Phase 4Active
- Sponsor
- Repha
- Start
- Oct 2019
- Countries
- 1
01
Overview
Phase 4 trial of Myrrhinil-Intest in Diarrhea-predominant irritable bowel syndrome (IBS-D) and irritable bowel syndrome (IBS) (2 arms), sponsored by Repha. Primary endpoint: Primary efficacy responder criterion. Started Oct 2019; status: active.
02
Drugs
Myrrhinil-Intest
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2019-000245-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000245-12.